Global Blood Transfusion Diagnostics Market set to reach $7.73 billion by 2032

From GlobeNewswire: 2025-07-02 10:37:00

The global Blood Transfusion Diagnostics Market was valued at USD 4.61 billion in 2023, projected to reach USD 7.73 billion by 2032, with a CAGR of 5.91%. Factors driving growth include increased demand for safe transfusions and advancements in automation and molecular testing for faster, more accurate results.

The U.S. Blood Transfusion Diagnostics Market was valued at USD 1.42 billion in 2023, expected to reach USD 2.23 billion by 2032, with a CAGR of 5.17%. Advanced healthcare infrastructure and technology adoption contribute to the market dominance in North America.

Major players in the market include Illumina, Thermo Fisher Scientific, Abbott Laboratories, Grifols, Siemens Healthineers, Roche Diagnostics, Beckman Coulter, and more. These companies offer a range of products and solutions for blood transfusion diagnostics.

The market is segmented by product (reagents & kits, instruments, others), application (blood grouping, disease screening), and end-use (hospitals, blood banks, diagnostics laboratories, others). North America holds the highest demand share, while the Asia-Pacific region is expected to record the fastest growth.

Blood banks play a crucial role in the market, accounting for 40.25% market share in 2023. Their role in testing, screening, and distribution of donated blood ensures transfusion safety and compliance with regulatory standards. The need for blood and its components globally drives the demand for blood transfusion diagnostics.

The disease screening segment led the market by application with a 62.32% market share in 2023. Stringent screening of infectious agents like HIV, Hepatitis, and malaria is essential for transfusion safety. Regulatory bodies mandate thorough screening of donated blood to prevent the spread of infections.



Read more at GlobeNewswire: Blood Transfusion Diagnostics Market Set to Reach USD 7.73